Podcasts about menarini

This episode covers:  Cardiology this Week: A concise summary of recent studies Coronary sinus reducer: promise in refractory angina Best strategies to reach LDL cholesterol goals in high-risk patients Snapshots Host: Susanna Price Guests: Carlos Aguiar, Rasha Al-Lamee, J. Wouter Jukema, Steffen Petersen Want to watch that episode? Go to: https://esc365.escardio.org/event/1807 Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Rasha Al-Lamee has declared to have potential conflicts of interest to report: speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Today we’re going to bring you an inside look into an Italian pharmaceutical firm with over 135 years of history. Founded in 1886 in Naples under the name of Farmacia Internazionale, our guest for today is from Menarini Group, a leading pharmaceutical and diagnostics company with a presence in over 140 countries. The firm prides itself as a leading provider of important healthcare brands, with its 18 manufacturing plants producing over 609 million packets of products a year. To this end, Menarini said it operates across the entire commercial value chain, from clinical development, regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields. That includes Consumer Health, Dermatology, Allergy or Respiratory, Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology or Specialty Care and more. All in, Menarini reported consolidated turnover of 4.375 billion euros in 2023, with international markets contributing 79% to the numbers. But how much of this is contributed by demand from the Asia-Pacific region? Meanwhile, Menarini is also seeing a number of interesting developments of late. For one thing, Menarini APAC had in June 2024 expanded its partnership with Pharmacosmos to tackle iron deficiency in patients in Singapore and Malaysia. So just how important are such licensing deals and partnerships in helping Menarini broaden its offerings while lowering R&D costs? On Under the Radar, Money Matters’ finance presenter Chua Tian Tian posed these questions to Glen Godresse, CEO, Menarini APAC.See omnystudio.com/listener for privacy information.

FIRENZE (ITALPRESS) - Riflessioni, aneddoti e retroscena inediti per raccontare il meglio dello sport. È stata una serata di straordinaria intensità per il talk show Fair Play Menarini – I campioni si raccontano. Correttezza, spirito olimpico e rispetto hanno fatto da trait d'union dell'evento, in cui grandi sportivi hanno affascinato il pubblico con le sfide e i successi del loro percorso. Il talk show, ambientato nella cornice suggestiva del Salone dei Cinquecento di Palazzo Vecchio a Firenze, si è dimostrato anche quest'anno un'occasione senza precedenti per mettere in risalto il significato e l'importanza del fair play.f10/xb8/gm/gtr

FIRENZE (ITALPRESS) - "Attraverso la storia di nove grandissimi campioni, Fondazione Fair Play Menarini racconta le loro storie sportive e umane che si intrecciano all'insegna del fair play. Son tutte storie bellissime, quella che mi ha colpito di più è quella di Rigivan". Lo ha dichiarato Filippo Paganelli, membro del Board della Fondazione Fair Play Menarini, a margine del talk show "Fair Play Menarini - I campioni si raccontano" ambientato nella cornice del Salone dei Cinquecento di Palazzo Vecchio a Firenze.f10/xb8/gm/gtr

FIRENZE (ITALPRESS) - "Attraverso la storia di nove grandissimi campioni, Fondazione Fair Play Menarini racconta le loro storie sportive e umane che si intrecciano all'insegna del fair play. Son tutte storie bellissime, quella che mi ha colpito di più è quella di Rigivan". Lo ha dichiarato Filippo Paganelli, membro del Board della Fondazione Fair Play Menarini, a margine del talk show "Fair Play Menarini - I campioni si raccontano" ambientato nella cornice del Salone dei Cinquecento di Palazzo Vecchio a Firenze.f10/xb8/gm/gtr

FIRENZE (ITALPRESS) - "Andy Diaz ha fatto qualcosa di straordinario e va raccontato. Ha una storia unica con valori importanti". Lo ha dichiarato il tecnico azzurro del Salto triplo Fabrizio Donato, a margine del talk show "Fair Play Menarini - I campioni si raccontano" ambientato nella cornice del Salone dei Cinquecento di Palazzo Vecchio a Firenze. "Sono emozionato per il bronzo, la mia rinascita nello sport ad alto livello e raggiungere questo obiettivo era il minimo che potevo fare per l'Italia e per tutti quelli che mi hanno aiutato in questo percorso" le parole dell'azzurro. f10/xb8/gm/gtr

FIRENZE (ITALPRESS) - "Andy Diaz ha fatto qualcosa di straordinario e va raccontato. Ha una storia unica con valori importanti". Lo ha dichiarato il tecnico azzurro del Salto triplo Fabrizio Donato, a margine del talk show "Fair Play Menarini - I campioni si raccontano" ambientato nella cornice del Salone dei Cinquecento di Palazzo Vecchio a Firenze. "Sono emozionato per il bronzo, la mia rinascita nello sport ad alto livello e raggiungere questo obiettivo era il minimo che potevo fare per l'Italia e per tutti quelli che mi hanno aiutato in questo percorso" le parole dell'azzurro. f10/xb8/gm/gtr

FIRENZE (ITALPRESS) - Riflessioni, aneddoti e retroscena inediti per raccontare il meglio dello sport. È stata una serata di straordinaria intensità per il talk show Fair Play Menarini – I campioni si raccontano. Correttezza, spirito olimpico e rispetto hanno fatto da trait d'union dell'evento, in cui grandi sportivi hanno affascinato il pubblico con le sfide e i successi del loro percorso. Il talk show, ambientato nella cornice suggestiva del Salone dei Cinquecento di Palazzo Vecchio a Firenze, si è dimostrato anche quest'anno un'occasione senza precedenti per mettere in risalto il significato e l'importanza del fair play.f10/xb8/gm/gtr

Dr. Linda Duska and Dr. Domenica Lorusso discuss the practice-changing results of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, which evaluated pembrolizumab plus chemoradiotherapy as treatment for previously untreated, high-risk, locally advanced cervical cancer. TRANSCRIPT  Dr. Linda Duska: Hello, I'm Linda Duska, your guest host of the ASCO Daily News Podcast today. I'm a professor of obstetrics and gynecology and serve as the associate dean for clinical research at the University of Virginia School of Medicine. On today's episode, we'll be discussing a new standard of care for previously untreated, high- risk locally advanced cervical cancer. This follows the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, which I will be referring to as KEYNOTE-A18 for the rest of this podcast, which demonstrated that pembrolizumab plus chemoradiotherapy improved both progression-free and overall survival compared to chemoradiotherapy alone. I was a co-author of this study, and I'm delighted to be joined today by the study's lead investigator, Dr. Domenica Lorusso, for today's discussion. She is also a professor of obstetrics and gynecology. She's at Humanitas University Rosano and the director of the Gynecologic Oncology Unit at the Humanitas Hospital San Pio in Milan, Italy. Our full disclosures are available in the transcript of this episode. Dr. Lorusso, it's great to be speaking with you today. Dr. Domenica Lorusso: Thank you, Linda. It's a great pleasure to be here. Thank you. Dr. Linda Duska: So I was hoping you could start us out with some context on the challenges associated with treating patients with high-risk, locally advanced cervical cancer. Dr. Domenica Lorusso: Yes. I have to make a disclosure because in my experience as a gynecologist, cervical cancer patients are the most difficult patients to treat. This is a tumor that involves young patients [who often have] small kids. This is a very symptomatic tumor. More than 50% of patients report pain. Sometimes the pain is difficult to control because there is an infiltration of the pelvic nerves and also a kind of vaginal discharge, so it's very difficult to treat the tumor. Since more than 25 years, we have the publication of 5 randomized trials that demonstrate that when we combine platinum chemotherapy to radiation treatment, we increase overall survival by 6%. This is the new standard of care – concurrent chemoradiation plus brachytherapy. This is a good standard of care because particularly modern, image-guided radiotherapy has reported to increase local control. And local control in cervical cancer translates to better overall survival. So modern radiotherapy actually is able to cure about 75% of patients. This is what we expect with chemoradiation right now. Dr. Linda Duska: So what are the key takeaways of A18? This is a really exciting trial, and you've presented it a couple of times. Tell us what are the key takeaways that you want our listeners to know. Dr. Domenica Lorusso: Linda, this is our trial. This is a trial that we did together. And you gave me the inspiration because you were running a randomized phase 2 trial exploring if the combination of pembrolizumab to concurrent chemoradiation was able to give signals of efficacy, but also was feasible in terms of toxicity. There were several clinical data suggesting that when we combine immunotherapy to radiotherapy, we can potentially increase the benefit of radiotherapy because there is a kind of synergistic effect between the two strategies. Radiotherapy works as a primer and immunotherapy works better. And you demonstrated that it was feasible to combine immunotherapy to concurrent chemoradiation. And KEYNOTE-A18 was based on this preliminary data. We randomized about 1,060 patients to receive concurrent chemoradiation and brachytherapy or concurrent chemoradiation and brachytherapy in combination with pembrolizumab followed by pembrolizumab for about two years. Why two years? Because in more than 80% of cases, recurrence in this patient population occurred during the first two years. So the duration of treatment was based on the idea to provide protection to the patient during the maximum time of risk. And the trial had the two primary endpoints, progression free and overall survival, and met both the endpoints, a significant 30% reduction in the risk of progression that was confirmed. At the 3-year follow up, the observation was even better, 0.68. So 32% reduction in the risk of progression. And more importantly, because this is a curative setting, 33% reduction in the risk of death was reported in the experimental arm when pembro was combined with chemoradiation. Dr. Linda Duska: That's amazing. I wanted to ask you, a prior similar study called CALLA was negative. Why do you think A18 was positive? Dr. Domenica Lorusso: Linda, there are several discussions about that. I had the possibility to discuss several times with the PI of CALLA, Brad Monk. The idea of Brad is that CALLA was negative because of using durvalumab instead of PD-1 inhibitor, which is pembrolizumab. I do not have exactly the same impression. My idea is that it's the kind of patient population enrolled. The patient population enrolled in KEYNOTE-A18 was really a high-risk population; 85% of that patient were node positive, where the definition of node positivity was at least 2 lymph nodes in the pelvis with a short diameter of 1.5. So, we are very confident this patient was node-positive, 55% at the grade 3 and 4 diseases. So this is really a high-risk population. I remember at the first presentation of CALLA, I was honored to discuss the CALLA trial when it was first presented at IGCS a few years ago. And when I received the forest plot of Calla, it was evident to me that in patients with stage III and node positive there was a signal of efficacy. And we have a huge number of patients with node positive. So in my opinion this is the reason why KEYNOTE-A18 is positive. Dr. Linda Duska: Yeah, I agree with you. I've thought about it a lot and I think you're right about that. The INTERLACE trial results were recently published. How should we interpret these results in the context of A18? Dr. Domenica Lorusso: So it's very difficult to compare the 2 trials. First of all, in terms of population. The population enrolled in INTERLACE is a low-risk, locally advanced but low risk population; 76% were stage II, 10% were stage I, 60% were node-negative patients. So, first of all, the population is completely different. Second is the type of radiotherapy that was provided. INTERLACE is a 10-year long trial, but in 10 years the quality and the technique of radiotherapy completely changed. Only 30% of patients in INTERLACE received what we call the modern image-guided brachytherapy, which is important because it provides local control and local control increases overall survival. And third, we read the paper. I'm not a methodologist, but there are some methodological biases in the paper. All the statistical design of the trial was based on PFS, but PFS was evaluated at physician description. And honestly, I never saw a trial that had no pre-specified timeline for radiological evaluation. It's very difficult to evaluate progression in cervical cancer because the fibrosis related to radiotherapy changes the anatomy in the pelvis. And I think that the radiological evaluation is important to address if the patient is progressing or not. Particularly, because the conclusion of CALLA is that the PFS was mainly in favor of distant metastasis. So really, it's difficult for me to understand how distant metastasis may be evaluated with the vagina visit. So really, it's very difficult to compare the two trials, but I have some concerns. And also because of toxicity in the study, unfortunately 30% of patients did not complete concurrent chemoradiation because of residual toxicity due to induction chemotherapy. So I wanted to be sure in the context of modern radiotherapy, if really induction chemo adds something to modern radiotherapy. Dr. Linda Duska: Well, I have two more questions for you. As we move immunotherapy into the front line, at least for these high risk locally advanced cervical cancer patients that were eligible for A18, what does that mean then for hopefully those few that develop recurrence in terms of second line therapy? Dr. Domenica Lorusso: Well, Linda, this is a very important question. We do not have data about immuno after immuno, but I would not completely exclude this hypothesis because in KEYNOTE-A18, the patient received treatment for a well-defined time period. And for those patients not progressing during immunotherapy, I really guess if there is a space for the reintroduction of immunotherapy at the time of recurrence. In this moment we have 30% of patients in KEYNOTE-A18 in the control arm that receive immunotherapy after progression, but still we have 11% of patients that receive immunotherapy in combination with concurrent chemoradiation and then receive, again, immunotherapy in later line of therapy. I think we need to collect these data to capture some signals and for sure we have the new drug. We have antibody drug conjugate. The trials are ongoing exploring the role of antibody drug conjugate, particularly in immune pretreated patients. So I think this is a very interesting strategy. Dr. Linda Duska: I was going to ask you, “What are the next steps,” but I think you already answered that question. You talked about the second line. If you were going to redesign a study in the frontline, what would it look like? Dr. Domenica Lorusso: Probably one question that I would like to answer – there are two questions in my opinion in KEYNOTE-A18 – one is induction immunotherapy. Linda, correct me if I'm wrong, you reported very interesting data about the immune landscape change when you use induction immunotherapy. And I think this is something that we need to explore in the future. And the second question is the duration of maintenance. Because, again, we decided for two years based only on the epidemiology of recurrence, but I guess if one year may be enough. Dr. Linda Duska: I think this sequencing question is really important, that the induction immunotherapy was actually GY017. I can't take credit for that, but I think you're right. I think the sequencing question is really important. Whether you need the concurrent IO or not is an important question. And then to your point about the 2 years, the length of the need for maintenance therapy is a question that we don't know the answer to. So there are lots of really important questions we can continue to ask. I want to thank you so much for sharing your valuable insights with us on the podcast today. You're always so thoughtful about this particular study and cervix cancer in general and also for your great work to advance the care for patients with GYN cancers. Dr. Domenica Lorusso: Thank you, Linda. It's our work - we progress together. Dr. Linda Duska: Yes. And we thank the patients as well. The over 1,000 patients that went on this trial during a pandemic. Right? Dr. Domenica Lorusso: Absolutely. Without their generosity and their trust, we would not be able to do this trial. Dr. Linda Duska: So we're very grateful to them and we thank our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you all.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:  Dr. Linda Duska @Lduska Dr. Domenica Lorusso   Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures:   Dr. Linda Duska: Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn Dr. Domenica Lorusso: Consulting or Advisory Role: PharmaMar, AstraZeneca, Clovis Oncology, GSK, MSD, Genmab, Seagen, Immunogen, Oncoinvest, Corcept, Sutro Biopharma, Novartis, Novocure, Daiichi Sankyo/Lilly Speakers' Bureau: AstraZeneca, Clovis, GSK, MSD, ImmunoGen, Seagen Research Funding (Inst.): PharmMar, Clovis, GSK, MSD, AstraZeneca, Clovis Oncology, Genmab, Seagen, Immunogen, Incyte, Roche, Pharma&, Corcept Therapeutics, Alkermes Travel, Accommodations, Expenses: AstraZeneca, Clovis, GSK, Menarini  

TITULARES 1 Facultad de Ciencias inauguró la Semana de la Carrera de Física Armando Euceda 2 Médico residente de la UNAH gana premio centroamericano Menarini a la excelencia académica   3 Realizan III Encuentro Nacional de Comunidades de Aprendizaje en la UNAH 4 Instituto Tecnológico de Costa Rica, realizó Feria de Empleo de Procomer en la Zona Norte

WASHINGTON (STATI UNITI) (ITALPRESS) - Il presidente del Friuli Venezia Giulia Massimiliano Fedriga, l'ambasciatrice italiana negli Stati Uniti Mariangela Zappia, l'oncologo Antonio Giordano, il presidente di AmCham Stefano Lucchini, il general manager di Ita Airways Massimo Allegri e il presidente della Fondazione De Gasperi Angelino Alfano: sono loro i premiati della seconda edizione degli Italpress Awards. Il premio è stato istituito dall'agenzia di stampa fondata e diretta da Gaspare Borsellino per valorizzare le relazioni tra Stati Uniti e Italia nel mondo degli affari, della cultura, dei media ed è stato consegnato a Washington in occasione del weekend di Gala del 49mo Anniversario della NIAF, la National Italian American Foundation con la quale Italpress, ha siglato recentemente una partnership triennale. Un accordo che “amplificherà la voce della Niaf, aprendo nuove opportunità per i giovani italoamericani che intraprendono una carriera nei media e nella comunicazione”, ha detto il presidente Robert Allegrini, facendo riferimento agli stage che la Fondazione e Italpress promuoveranno insieme per giovani laureati proprio in virtù della partnership.“Un'agenzia crossmediale, con una presenza sempre più radicata all'estero. E' su questo che stiamo lavorando in questi anni. E' questo il nostro futuro. E gli Italpress Awards sono uno dei tasselli di questo progetto”, afferma Gaspare Borsellino. “L'informazione libera e responsabile è fondamentale per garantire la democrazia di un Paese. Il grado di conoscenza e di informazione responsabile determinano la libertà delle persone”, ha affermato il governatore Fedriga. Sulla stessa lunghezza d'onda l'ambasciatrice Zappia: “Bisogna sottolineare con forza il ruolo che hanno la stampa e la comunicazione sul lavoro di tutti noi”, è proprio quello che fanno iniziative come gli Italpress Awards, ha affermato.Alla cerimonia, oltre ai premiati, hanno partecipato tra gli altri anche la senatrice Maria Stella Gelmini, l'amministratore delegato dell'Enav, Pasqualino Monti, il commissario straordinario per il sisma del 2016 Guido Castelli, il giornalista Gianni Riotta.Official sponsor dell'evento Enel, GKSD, Menarini e Webuild.xp6/mrv/abr/gsl

WASHINGTON (STATI UNITI) (ITALPRESS) - Il presidente del Friuli Venezia Giulia Massimiliano Fedriga, l'ambasciatrice italiana negli Stati Uniti Mariangela Zappia, l'oncologo Antonio Giordano, il presidente di AmCham Stefano Lucchini, il general manager di Ita Airways Massimo Allegri e il presidente della Fondazione De Gasperi Angelino Alfano: sono loro i premiati della seconda edizione degli Italpress Awards. Il premio è stato istituito dall'agenzia di stampa fondata e diretta da Gaspare Borsellino per valorizzare le relazioni tra Stati Uniti e Italia nel mondo degli affari, della cultura, dei media ed è stato consegnato a Washington in occasione del weekend di Gala del 49mo Anniversario della NIAF, la National Italian American Foundation con la quale Italpress, ha siglato recentemente una partnership triennale. Un accordo che “amplificherà la voce della Niaf, aprendo nuove opportunità per i giovani italoamericani che intraprendono una carriera nei media e nella comunicazione”, ha detto il presidente Robert Allegrini, facendo riferimento agli stage che la Fondazione e Italpress promuoveranno insieme per giovani laureati proprio in virtù della partnership.“Un'agenzia crossmediale, con una presenza sempre più radicata all'estero. E' su questo che stiamo lavorando in questi anni. E' questo il nostro futuro. E gli Italpress Awards sono uno dei tasselli di questo progetto”, afferma Gaspare Borsellino. “L'informazione libera e responsabile è fondamentale per garantire la democrazia di un Paese. Il grado di conoscenza e di informazione responsabile determinano la libertà delle persone”, ha affermato il governatore Fedriga. Sulla stessa lunghezza d'onda l'ambasciatrice Zappia: “Bisogna sottolineare con forza il ruolo che hanno la stampa e la comunicazione sul lavoro di tutti noi”, è proprio quello che fanno iniziative come gli Italpress Awards, ha affermato.Alla cerimonia, oltre ai premiati, hanno partecipato tra gli altri anche la senatrice Maria Stella Gelmini, l'amministratore delegato dell'Enav, Pasqualino Monti, il commissario straordinario per il sisma del 2016 Guido Castelli, il giornalista Gianni Riotta.Official sponsor dell'evento Enel, GKSD, Menarini e Webuild.xp6/mrv/abr/gsl

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology this Week: A concise summary of recent studies   Lifetime management of aortic valve stenosis   Spirituality and cardiovascular health  Statistics Made Easy: Statistical Analyses using Chat GPT  Host: Perry Elliott Guests: Carlos Aguiar, Kavitha Chinnaiyan, Francesco Maisano Want to watch that episode? Go to: https://esc365.escardio.org/event/1155   Disclaimer ESC TV Today and ESC 365, the cardiology knowledge hub are supported by Bristol Myers Squibb. The scientific content and opinions expressed in this programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Kavitha Chinnaiyan and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Giuseppe Biondi-Zoccai has declared to have potential conflicts of interest to report : Aleph, Amarin, Balmed, Cardionovum, Crannmedical, Endocore Lab, Eukon, Guidotti, Innovheart, Meditrial, Menarini, Microport, Opsens Medical, Terumo, and Translumina. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi, Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics. Francesco Maisano has declared to have potential conflicts of interest to report : Grant Institute, Edwards, Abbott, NVT, Medtronic, Jenavalve and Boston Scientifics. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.      

FIRENZE (ITALPRESS) - Le leggende dello sport al Teatro Romano di Fiesole per il 28° Premio Internazionale Fair Play Menarini. La manifestazione dedicata ai valori dell'etica, della lealtà e del rispetto ha celebrato i vincitori dell'edizione 2024, esempi di correttezza e sportività in gara e nella vita.Gli spettatori del Teatro Romano hanno salutato tra gli applausi icone del panorama internazionale. A cominciare da Samuel Eto'o, rappresentante del miglior calcio mondiale e gloria intramontabile del Camerun, il capitano della Nazionale campione del mondo 2006 Fabio Cannavaro e altri due pilastri degli Azzurri: Ciro Ferrara, vice campione a Euro 2000, e Giuseppe Dossena, "eroe di Spagna" al Mundial '82. A chiudere il roster del calcio Cesare Prandelli, che ha portato la Nazionale italiana al secondo posto agli Europei del 2012.col/abr/gtr

Etica, lealtà e rispetto: il premio Fair Play Menarini giunto alla 28ma edizione ha premiato esempi di correttezza e sportività in gara e nella vita. Fra le atlete che hanno calcato il tappeto rosso dell'evento – al Teatro Romano di Fiesole -, la regina del pattinaggio di velocità Francesca Lollobrigida, trionfatrice ai campionati europei del 2018, e la velocista Ambra Sabatini, portabandiera italiana alle Paralimpiadi di Parigi. Per il basket c'era Marco Belinelli, fenomeno dell'NBA, mentre la pallavolo ha trovato il suo rappresentante di primo piano in Gian Paolo Montali, già commissario tecnico dell'Italvolley maschile due volte campione d'Europa. E poi Roberto Rigali, argento ai Mondiali di Budapest 2023 nella staffetta 4x100; la leggenda dei rally e della Formula 1 Cesare Fiorio e il più volte primatista mondiale dei pesi massimi Clemente Russo. Per il giornalismo sportivo Federico Buffa, voce e volto delle imprese dei grandi sportivi.A premiarli, coloro che li hanno preceduti nell'Albo d'Oro: gli Ambasciatori del Fair Play Menarini. Tra questi Federica Pellegrini, vincitrice dell'edizione 2022 e madrina dell'evento, insieme ai presentatori Rachele Sangiuliano e Omar Schillaci.abr/gtr

FIRENZE (ITALPRESS) - Ha esordito nel romantico scenario di Piazzale Michelangelo di Firenze il 28° Premio Internazionale Fair Play Menarini. La kermesse dedicata ai grandi valori dello sport proseguirà stasera con il gran finale al Teatro Romano di Fiesole. I vincitori del 2024 e gli Ambasciatori del Fair Play Menarini, portabandiera del gioco corretto in campo come nella vita, hanno animato il primo appuntamento del Premio sull'affaccio più elegante del capoluogo toscano.Rispetto dell'avversario e di sé stessi, educazione, socialità e corretto stile di vita, sono tutti valori che secondo il presidente della Regione Eugenio Giani, non vanno soltanto evocati ma messi in pratica e promossi, a tutti i livelli. col/abr/gtr

FIRENZE (ITALPRESS) - E' iniziato il conto alla rovescia per la cerimonia di premiazione del 28° Premio Internazionale Fair Play Menarini. Il fascino intramontabile del Teatro Romano di Fiesole farà da sfondo al momento più importante della kermesse. A condurre la serata conclusiva dell'evento, realizzato per la prima volta in partnership con Sky TG24, saranno Rachele Sangiuliano e Omar Schillaci, assieme a Federica Pellegrini, madrina del Premio. La cerimonia sarà trasmessa successivamente su Sportitalia.col/abr/gtr

ROMA (ITALPRESS) - Nuove stelle dello sport brillano nel firmamento del Premio Internazionale Fair Play Menarini. La manifestazione che ogni anno promuove i valori di etica, lealtà e rispetto si è aperta ufficialmente alSalone d'Onore del Coni con la presentazione della 28esima edizione, in programma il 3 e 4 luglio a Firenze e Fiesole. Annunciati nell'occasione i nomi dei premiati che la notte del 4 luglio riceveranno il prestigioso riconoscimento sul palco del Teatro Romano di Fiesole. spf/mc/gtr

Join renowned pulmonologists Klaus Rabe, MD, PhD, FERS, and Ian Pavord, DM, FRCP, FERS, as they discuss on-treatment clinical remission as a goal in asthma management beyond disease control, and highlight the role of type 2 inflammatory biomarkers in optimizing patient outcomes. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Ian D. Pavord, MA, DM, FRCP, FERS, FMedSci has received honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Inglehiem, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed. In 2014-5 he was an expert witness for a patent dispute involving Astra Zeneca and Teva.  Klaus Rabe, MD, PhD has served on FDA and EMA panels for registration of drug for COPD. He has served on advisory panels for AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, Sanofi & Regeneron, Berlin Chemie, Novartis, GlaxoSmithKline, Insmed, CSL Behring making asthma and COPD drugs, and participated in clinical trials. He has never worked with the tobacco industry (and never will). He has no shares or proprietary interests of any kind. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2303834 V1 02/2024 MAT-US-2402193 v1.0 - P Expiration Date: 02/26/2026

FIRENZE (ITALPRESS) - Per aiutare l'industria farmaceutica "il governo può lavorare molto sulla parte della burocrazia, può lavorare sulla parte degli incentivi, della formazione, perché abbiamo bisogno di tutti questi aspetti. Abbiamo bisogno di procedure che siano più rapide e che siano competitive con il resto dei paesi sia per registrare i nuovi farmaci che per fare le sperimentazioni cliniche, sia abbiamo bisogno di un recupero della parte dei costi industriali che ci stanno schiacciando. Abbiamo bisogno di nuove risorse formate nelle scuole e nelle università". Lo ha detto Lucia Aleotti, azionista e membro del Board di Menarini a margine di una conferenza stampa svoltasi quest'oggi nella sede della Camera di Commercio di Firenze.(ITALPRESS).xb8/trl

PARIGI (ITALPRESS) - L'azienda di medicina estetica italiana RELIFE, del gruppo Menarini, è presente al congresso Imcas a Parigi per presentare il proprio approccio Integrato RELIFE 5R che ricorre all'uso combinato di innovativi fili di trazione, filler, peeling e trattamenti topici per il volto. f09/mgg/mrv

PARIGI (ITALPRESS) - L'azienda italiana di medicina estetica RELIFE, del gruppo Menarini, è intervenuta al congresso Imcas a Parigi per presentare il proprio approccio Integrato RELIFE 5R che permette di raggiungere risultati naturali personalizzati grazie all'uso combinato di innovativi fili di trazione riassorbibili, filler, peeling e trattamenti topici per il viso. Adele Sparavigna, direttore dell'istituto Derming, si è focalizzata sulla nuova linea anti-aging nuova linea anti-aging Definisse Kp1 collagen modulator : “È molto importante lavorare a valle dei processi biosintetici della cellula creando uno scudo protettivo nei confronti della degradazione della fibra di collagene e dell'elastina nel derma”.f09/mgg/gtr

PARIGI (ITALPRESS) - L'azienda italiana di medicina estetica RELIFE, del gruppo Menarini, è intervenuta al congresso Imcas a Parigi per presentare il proprio approccio Integrato RELIFE 5R che permette di raggiungere risultati naturali personalizzati grazie all'uso combinato di innovativi fili di trazione riassorbibili, filler, peeling e trattamenti topici per il viso. L'obiettivo del medico di medicina estetica Vincent Wong è stato quello di creare un approccio più naturale al ringiovanimento del viso: “Questa tecnica vuole rivolumizzare la parte laterale del viso che spesso viene trascurata nella pratica della medicina estetica. Oltre alla volumizzazione, questa tecnica viene impiegata anche per sostenere i legamenti del viso per avere un effetto sollevante”.f09/mgg/gtr

PARIGI (ITALPRESS) - L'azienda italiana di medicina estetica RELIFE, del gruppo Menarini, è intervenuta al congresso Imcas a Parigi per presentare il proprio approccio Integrato RELIFE 5R che permette di raggiungere risultati naturali personalizzati grazie all'uso combinato di innovativi fili di trazione riassorbibili, filler, peeling e trattamenti topici per il viso. Il chirurgo plastico Salvatore Piero Fundarò ha approfondito il potenziale dei fili di trazione per la ridefinizione dei contorni del volto: “È fondamentale sia ridonare volume con l'acido ialuronico, ma anche riuscire a riposizionare, tramite i fili di sospensione, i tessuti molli che sono scesi verso il basso.f09/mgg/gtr

PARIGI (ITALPRESS) - L'azienda italiana di medicina estetica RELIFE, del gruppo Menarini, è intervenuta al congresso Imcas a Parigi per presentare il proprio approccio Integrato RELIFE 5R che permette di raggiungere risultati naturali personalizzati grazie all'uso combinato di innovativi fili di trazione riassorbibili (threads), filler, peeling e trattamenti topici per il viso. Stefanos Vourtsis, chirurgo plastico, si è dedicato all'approccio integrato di diversi trattamenti di medicina estetica: “L'utilizzo di fili e filler in contemporanea permette di evitare questi visi iper gonfiati e iper trattati che purtroppo vediamo tutti i giorni, non soltanto nei nostri studi, ma anche per strada”.f09/mgg/gtr

Professors Wytske Fokkens and Joaquim Mullol discuss the burden of smell loss and the emerging science on how inflammation drives olfactory dysfunction in patients with CRSwNP. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Professor Wytske Fokkens, MD, PhD has received consultation/speaker fees from Novartis, Sanofi, GSK and Dianosic.  Professor Joaquim Mullol, MD, PhD reports have received research grants, participated in clinical trials, been a member of Speaking Bureaus and Advisory Boards from Allakos, AstraZeneca, Glenmark, GSK, Menarini, MSD, Mitsubishi-Tanabe, Noucour/Uriach Group, Novartis, Optinose, Proctor & Gamble, Sanofi-Genzyme, Regeneron Pharmaceuticals, Viatris. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400013 v1.0 01/2024 MAT-US-24000221 v1.0 - P Expiration Date: 01/08/2026

In dieser Folge des CULTiTALK diskutieren der Host Georg Wolfgang und der Gast Kristian Redlich die Herausforderungen und Chancen von Stabilität, Veränderung und Kultur in Unternehmen. Dabei betonen sie die Bedeutung von klaren Zielen, transparenter Kommunikation und aktiver Gestaltung von formellen Regeln. Kristian Redlich, HR-Director bei Menarini von Heyden GmbH, spricht über die Unsicherheiten in Wirtschaft, Politik und kriegerischen Auseinandersetzungen, die zu Mitarbeiterüberforderung führen können.Die Diskussion beleuchtet die Bedeutung von Tradition und Moderne in einem Unternehmen mit langer Geschichte. Die beiden tauschen ihre Ansichten über die Notwendigkeit einer aktiven Veränderung von Unternehmenskultur und Strukturen aus. Sie betonen, dass eine bloße Veränderung von Betriebsvereinbarungen oder des Organigramms allein nicht ausreicht, um Verhaltensänderungen zu bewirken.Georg und Kristian diskutieren zudem die Wichtigkeit von Reflexion in der Personalauswahl und Personalentwicklung und betonen die Notwendigkeit eines Dialogs über zukünftige Führungspraktiken und -ziele. Sie unterstreichen die Bedeutung, nicht nur formelle Regeln zu interpretieren, sondern diese aktiv zu gestalten, insbesondere für Führungskräfte.Trotz möglicher Unterschiede zeigen die Gesprächspartner ein hohes Maß an Komplementarität in ihren Meinungen. Zum Schluss betonen sie die Vielfalt und die Grau-Stufen des Lebens. Diese Folge bietet faszinierende Einblicke in die Veränderungs- und Kulturthemen in Unternehmen sowie die Bedeutung von klaren Zielen und aktiver Gestaltung von Regeln. Alle Links zu Kristian Redlich:LinkedIn: https://www.linkedin.com/in/kristian-redlich-b57097139/Unternehmen: https://www.menarini.com/en-us/ Alle Links zu Georg und dem Culturizer:Georg: https://www.linkedin.com/in/georg-wolfgangCulturizer: https://culturizer.appCULTiTALK: https://cultitalk.de

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Discover shared and unique features of type 2 inflammatory diseases and how multi-disciplinary care can benefit patients. Join Profs. Klaus Rabe and Stephan Weidinger as they explore how chronic underlying type 2 inflammation manifests in different organs to drive pathology in atopic dermatitis, prurigo nodularis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis; and discuss how these commonalities translate into shared decision-making and multidisciplinary care in clinical practice. ADVENT is a medical education non-promotional for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Klaus Rabe, MD, PhD: Grants and research support: German Federal Ministry for Research and Technology (BMFT); Honoraria or consultation fees: AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, Sanofi, Regeneron, Verona Pharma; Other support/potential conflict of interest: Director of the Airway Research Center North (ARCN) within the Deutsche Zentrum für Lungenforschung (DZL) Stephan Weidinger, MD, PhD: Speaker, advisory board member, and or investigator for: AbbVie, Almirall, Galderma, Kymab, Leo Pharma, Lilly, Pfizer, Regeneron, Sanofi, Boehringer Ingelheim © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2302410 v2.0 07/2023 MAT-US-2304930 v1.0-P Exp. Date 07/07/2025

FIRENZE (ITALPRESS) - Il dirigente interista premiato nell'ambito della 27esima edizione del tradizionale premio Fair Play Menarini a Firenze. xb8/gm/gtr

"Siamo molto contenti di questa 27esima edizione del premio fair play Menarini, è bello premiare grandi sportivi che hanno avuto carriere basate sulla correttezza e sulla lealtà". Così Lucia Aleotti azionista e membro del consiglio di amministrazione del gruppo Menarini.xb8/ari/gtr

"Portare avanti i valori sani del calcio e dello sport incarnati anche da Paolo è sempre un piacere e il premio fair play Menarini è l'occasione giusta per trasmettere principi importanti". Così la moglie del compianto Paolo Rossi, a margine di un evento legato al premio Fair Play Menarini.xb8/ari/gtr

L'ex campionessa azzurra premiata nell'ambito della 27esima edizione del tradizionale premio Fair Play Menarini a Firenze.xb8/gm/gtr

"I tecnici azzurri hanno poco tempo per allenare le squadre e il calcio italiano non ha mai avuto uno stile. Se Mancini riuscisse a invertire la tendenza farebbe un capolavoro", dice l'ex ct della Nazionale, impegnato a Firenze in qualità di ambasciatore del premio Fair Play Menarini.xb8/ari/gtr

Drs. Allison Zibelli and Arielle Heeke discuss the NATALEE trial's novel approach to high-risk HR+ breast cancer, the potential of delaying CDK4/6 inhibitors in HR+, HER2-negative mBC to decrease toxicities and costs in the SONIA trial, and de-escalation strategies in HER2+ early-stage breast cancer. TRANSCRIPT Dr. Allison Zibelli: Hello. I'm Dr. Allison Zibelli, your guest host for the ASCO Daily News Podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Cancer Center at Jefferson Health in Philadelphia. My guest today is Dr. Arielle Heeke, a breast medical oncologist at the Levine Cancer Institute at Atrium Health in North Carolina.  Today, we'll be discussing practice-changing studies and other key advances in breast cancer that were featured at the 2023 ASCO Annual Meeting.   Our full disclosures are available in the show notes and disclosures of all guests on the podcast can be found on our transcripts at asco.org/DNpod.   Arielle, it's great to speak with you today.   Dr. Arielle Heeke: Thank you so much for having me.  Dr. Allison Zibelli: Let's start with LBA500. This was the NATALEE trial of ribociclib and endocrine therapy as adjuvant treatment in patients with hormone receptor-positive HER2-negative early breast cancer. What are your key takeaways from the study, and how do you think this changes our approach to high-risk ER-positive breast cancer?  Dr. Arielle Heeke: Yeah, this was definitely the study for which many of us were waiting to see the results. It was exciting to see the results come through so quickly. As you mentioned, the NATALEE trial was a phase 3 study that evaluated three years of adjuvant ribociclib at a dose of 400 milligrams, which is a little different than what we're used to in the metastatic space at 600 milligrams. But essentially, it randomized patients to receive this 400-milligram dose with their adjuvant aromatase inhibitor therapy versus just the standard of care adjuvant endocrine therapy in patients that are high risk with early-stage breast cancer.   What made NATALEE somewhat unique is they defined high risk a little bit more broadly than we've seen in previous studies, such as monarchE. So, what I mean by that is NATALEE enrolled patients with stage 2 and 3 early-stage breast cancer. And notably, they allowed for patients that were lymph node-negative but had some other high-risk features, such as a grade 3 tumor or a grade 2 tumor with high-risk genomics, such as oncotype or a high Ki-67. So, by broadening who was eligible, NATALEE captured more patients at risk for recurrence. Of course, we know that recurrence is not specific for patients with lymph node-positive disease. We can see recurrence even with stage 1, but certainly, we start to see more recurrence risk as patients drift into stage 2 and stage 3.   In the NATALEE study, the majority of these patients did receive prior chemotherapy, which I also think is interesting. We've kind of seen in the metastatic space that sometimes chemotherapy can augment patients' responsiveness to CDK4/6 inhibitors. But specifically in NATALEE, 88% of patients had received prior chemotherapy, and ultimately, about a third of the patients were lymph node-negative.   So, diving into some of the results with this first analysis that we saw at ASCO, with the median follow-up for invasive disease-free survival of just 27.7 months, they were able to show that the risk for invasive disease was reduced by 25.2% with the addition of ribociclib plus endocrine therapy compared to endocrine therapy alone. And this three-year invasive disease-free survival rate was 90.4% for the combination therapy compared to 87.1% for endocrine therapy alone, which is an absolute difference of 3.3%. Additionally, patients treated with ribociclib and endocrine therapy had a 26.1% reduced risk for distant disease-free survival compared with endocrine therapy alone, and this was a rate of 90.8% for ribociclib with endocrine therapy compared to 88.6% with endocrine therapy alone, which correlates to an absolute benefit of 2.2%.    They did show results for overall survival as well, but again, follow-up was just a median of 27.7 months. So, data was essentially immature to show any true overall survival benefit from this approach. And in fact, only 20% of patients had completed three years of ribociclib at this data cutoff. And as a reminder, again, NATALEE involved ribociclib for three years compared to two years, which we've seen with other studies in this space.   Also, what was encouraging from NATALEE were the readouts for toxicities. Neutropenia is definitely a concern with this class of medication, and they were able to show that rates of neutropenia were overall lower than what we've seen in the pooled data in the metastatic space. And also that problematic QTc prolongation for which we have to get EKGs baseline two weeks and four weeks. They also showed that the likelihood of having QTc prolongation on this therapy was significantly less at that 400-milligram dose compared to 600.   I think the key takeaway is yes, this drug is effective as adjuvant therapy, which is perhaps not surprising since we've seen such promising results in the metastatic space, but numerically not as striking as what we have at this point with adjuvant abemaciclib, but of course, this is a newer study. We hope to see that continued separation of the curves as we were fortunate enough to see with the abemaciclib data, but obviously we'll be looking for additional analyses from NATALEE.    And then how this will change practice, of course, we'll have to wait to see if the therapy is approved for use in the adjuvant setting for early-stage hormone receptor-positive breast cancer, but it certainly will be a nice option for patients that struggle with GI toxicity kind of at baseline. But also, if they were previously on abemaciclib and were not able to tolerate due to the GI toxicity, this would be an option for them. Also, as mentioned, it's a broader patient population, so we can consider this perhaps for a patient with lymph node-negative disease.   Although we will have to ask ourselves that just because someone meets eligibility for the NATALEE  study, and if the therapy is ultimately approved, is it appropriate to give it to all those patients? Or do we need to still kind of think of this in the setting of the highest-risk patient, not just any patient with stage 2 plus disease? There was a lot of talk at the meeting, certainly about biomarkers and potentially using ctDNA to try to find these predictors of benefit from CDK4/6 inhibitor therapy, but obviously, still a long way to go before we can use that type of technology in this space.  Dr. Allison Zibelli: Thank you. Staying on the topic of CDK4/6 inhibitors, everybody was excited about the SONIA trial, which was LBA1000, and this trial was asking if we can delay using CDK4/6 inhibitors for newly diagnosed ER-positive HER2-negative metastatic breast cancer as a way to decrease both toxicity and cost. Tell us about this study.  Dr. Arielle Heeke: The SONIA trial was such a cool study to see, and the presenter reported findings in such a thought-provoking way. Really great to see this sort of work being done because I think we all wonder deep down in our gut, if more is more, or if we do need to kind of be a little bit more thoughtful about how we introduce these therapies certainly from a patient perspective. Patients that participate at ASCO [meetings] have been saying for years how important it is to consider the toxicities in terms of side effects, but also, of course, financial toxicities. So, it was great to see the SONIA trial at center stage.   Essentially, as you mentioned, it was a study that randomized patients in the first-line setting with metastatic hormone receptor-positive breast cancer to receive either first-line CDK4/6 inhibitor therapy or second-line CDK4/6 inhibitor therapy. So basically, there was a mandated crossover, so patients that received the CDK4/6 inhibitor first-line did not receive a second line and vice versa. Patients that were randomized to receive their endocrine therapy as monotherapy first line went on to receive CDK4/6 inhibitor at second-line. And the second-line endocrine therapy was fulvestrant in both of those situations.    We kind of run into this problem with patients now where we have so many therapies available to us that we don't typically run out of treatment options, but rather we run up against treatment toxicity or ultimate failure of the human body to keep up with the demands of ongoing therapy. So, again, while it's maybe somewhat attractive to start treatments earlier using things first-line rather than second-line or longer, just kind of post-CDK4/6 inhibitor progression, you know using this CDK4/6 inhibitor again with a different endocrine therapy backbone is probably not offering a meaningful benefit to that many patients. So this type of study is so necessary to really try to help us frame who needs those therapies sooner and longer or perhaps is there a substantial portion of patients that we don't need to put them through that sort of toxicity.   So that's the SONIA trial. Some things to note about the patient population, these patients were a bit older than what we've seen in some of our metastatic CDK4/6 inhibitor trials. There was a median age of 64 and 87% were postmenopausal. Additionally, just 40% had received prior chemotherapy. And as is true for most of our studies, 91% have received palbociclib on study with just 8% receiving ribociclib. And the choice of the CDK4/6 inhibitor was per the treating provider, and at the time of the of study globally, palbociclib was the more commonly prescribed CDK4/6 inhibitor. But over the last year or so, data has certainly emerged favoring ribociclib in the metastatic setting.   On the SONIA trial, patients were monitored for a median of 37.3 months. And looking at the primary endpoint of the second progression-free survival, which is defined as the time for random assignment to the second objective disease progression or death, for those patients who received first-line CDK4/6 inhibition, had a PFS2 of 31 months compared to 26.8 months with second-line CDK4/6 inhibitor use. And this slight difference was non-statistically significant. So the conclusion was that time to second progression was not impacted by whether or not a patient received first-line CDK4/6  inhibition or second-line CDK4/6 inhibition. Additionally, there were no differences in overall survival between the 2 arms with a median overall survival of 45.9 months with first-line CDK4/6 inhibitor use versus 53.7 months in second-line CDK4/6 inhibitor use.  And that actually equates to significant differences in time on drug. The median duration of CDK4/6 inhibitor use with first-line therapy was 24.6 months compared to 8.1 months with second-line use. And by being on therapy for an additional 16.5 months if you use CDK4/6 inhibitor first-line, this, of course, leads to increased toxicity and certainly increased financial burden. And it was estimated that for each patient that receives this therapy first-line, there is an additional $200,000 spent on getting them the CDK4/6 inhibitor first-line, whereas the results from SONIA suggested that whether you use it first-line or second-line, the outcomes are essentially exactly the same.   And then specific for the SONIA trial, by conducting the study, they saved approximately €25 million on drug expenditure during the conduct of the trial. It's just amazing when you take it to that scale. And then lastly just to mention, they looked at quality of life assessments as well and there were no differences in the two arms whether they got first-line or second-line CDK4/6 inhibition.  Dr. Allison Zibelli: I thought this study was remarkable, and it got a long ovation when it was presented at the meeting. I'm certainly going to use this strategy and prioritize who needs upfront CDK4/6 inhibitor therapy.  I think that we have to think of not just drug toxicity for our patients, but financial toxicity. A lot of these drugs have very high copays and the number one cause of bankruptcy in the United States is medical costs. So that's something we really have to keep in mind. I also thought it was very interesting that the study was designed in cooperation with the patient advocacy group and patients themselves were very enthusiastic about this study and helped design it and helped recruit to it. So all in all, I thought this was a remarkable study.    So moving on, LBA1013 was the TORCHLIGHT study of toripalimab versus placebo in combination with nab-paclitaxel for patients with metastatic or recurrent triple-negative breast cancer. Many of us are not familiar with toripalimab. Can you tell us about the drug and how it was used in this study?  Dr. Arielle Heeke: Yes, toripalimab is essentially an immunotherapy agent. It's an IgG4K monoclonal antibody that targets PD-1. In this study, TORCHLIGHT, patients were randomized to receive toripalimab versus placebo in combination with nab-paclitaxel in newly metastatic triple-negative breast cancer. The patients on study were randomized two to one to receive drug or placebo. The drug is given on day 1 of a 3-week cycle at 240 milligrams and then patients of course also receive nab-paclitaxel on a day 1 and day 8 schedule of a 21-day cycle. They did look at outcomes on the study based on PD-L1 positivity status and they assessed for PD-L1 with an IHC assay JS311 antibody that ultimately generated a combined positive score. And PD-L1 positivity was defined as a CPS of greater than or equal to one based off of this assay. In the study population, about a third of patients were- patients' tumors were CPS negative, a third had a CPS of 1 to 10 and about a quarter had a CPS of greater than or equal to 10. And then approximately 7% of the tumors had an unknown status.   And then getting right into the results, we were provided results in the PD-L1 positive subgroup as well as the whole patient population. Looking at the primary endpoint of PFS, there were significant improvements seen in median PFS with the addition of toripalimab to nab-paclitaxel, again in the first line setting with a median PFS of 8.4 months with the addition of the immunotherapy agent versus 5.6 months with placebo. And this was statistically significant.  And then in the intent to treat population, there were some numeric improvements, in median, progression-free survival at 8.4 months with the addition of toripalimab versus 6.9 months with placebo.   We also got some results with overall survival that were quite intriguing, although this initial analysis was not designed to necessarily prove statistically significant differences in overall survival. But again, there were some promising trends. Looking first at the PD-L1 positive subgroup, the median overall survival was 32.8 months with the addition of toripalimab versus 19.5 months with placebo. Breaking it down a little bit further based on CPS values, for a CPS of 1 to 10, median overall survival was 32.8 months versus 19.5 months. And then for those very high CPS or greater than or equal to ten, median overall survival was not reached in this group versus 18.3 months with placebo. Also, looking in the intent-to-treat population, there were also improvements in overall survival with the addition of toripalimab with a median overall survival of 33.1 months with the addition of immunotherapy versus 23.5 months with nab-paclitaxel alone. So potentially, depending on next steps of this study, we would potentially have an option to add immunotherapy that is not biomarker specific, meaning we can potentially provide toripalimab to all patients regardless of their PD-L1 status.  Dr. Allison Zibelli: Very interesting new drug to look forward to. So, one of the major themes of this year's meeting was de-escalation strategies. For example, LBA506 reported the three-year invasive disease-free survival of the PHERGain trial, which looked at eliminating chemotherapy for HER2-positive patients getting neoadjuvant therapy. Tell us about the design of this study and how will it impact the care of these patients?   Dr. Arielle Heeke: The design was very complicated. I had to look at it a few times to really make sure I got my head around it. But I think once you do figure it out, you can see how there might be a path forward in clinical practice. Although I think for all of this work, it's maybe not ready yet for primetime, but certainly thought-provoking. But the PHERGain clinical trial, I feel like we've heard about this study for a little while and this concept of de-escalation really kind of started in the HER2-positive space. But this study was a randomized study of chemotherapy de-escalation and early HER2-positive breast cancer using PET/CT as a marker of response to therapies that don't involve chemotherapy.   Patients were eligible for the study if they had stage 1 to 3a HER2-positive breast cancer with no prior therapy for breast cancer, and ultimately 356 patients were enrolled in a 1 to 4 randomization scheme with the majority of patients ultimately enrolled into the experimental group, which is called Group B. So, to break down Group A and Group B, Group A essentially were patients that receive typical standard of care, which at this point is TCHP for six cycles, neoadjuvantly or prior to surgery. Once they complete those cycles they move into surgery and then Herceptin-PERJETA adjuvantly for additional twelve cycles.  I should also note that this study was conducted prior to results of the KATHERINE trial that showed benefit of switching to adjuvant T-DM1 if there's residual disease. So, patients in Group A as well as Group B did not receive T-DM1 at any point. So, again, Group A is kind of your standard of care. Group B was the “experimental arm.” And so, what they did in this arm to assess potential de-escalation strategies, patients first received Herceptin-PERJETA alone for two cycles with or without endocrine therapy, if they were also hormone receptor-positive. But after those two cycles, they underwent a PET/CT, and then if a response was garnered, they would continue with Herceptin-PERJETA and again plus or minus endocrine therapy to complete six cycles total before proceeding on with surgery. Then if they were fortunate enough to achieve complete response at the time of surgery, then they just continued with Herceptin-PERJETA maintenance, whereas if they did not achieve a complete response at the time of surgery, then they actually received TCHP 6 times adjuvantly. So, the chemotherapy was introduced after surgery.   And then going back to that PET/CT time point, if patients did not achieve a response at that check-in point, after 2 cycles of Herceptin-PERJETA, at that point they were transitioned to chemotherapy with TCHP, again, for six cycles. So, either they could kind of ride all the way through if they got that complete response at the time of surgery with Herceptin-PERJETA only, or if at surgery there was residual disease, they went on to receive TCHP after surgery, or if they did not have a response on that interim PET/CT after 2 cycles of HP then they would go on to receive TCHP neoadjuvantly.    So, looking at the results, they actually had 2 primary endpoints. The first primary endpoint was rates of a complete response at the time of surgery in patients that had a PET response. So, PET responses were actually seen in nearly 80% of all the patients treated with Herceptin-PERJETA without chemotherapy. And in those PET responders, a complete response rate at the time of surgery was seen in approximately 38% of patients. So, 37.9% of PET responders actually achieved a complete response when they went to surgery after receiving Herceptin-PERJETA alone, which is pretty amazing. I mean, we're used to seeing higher complete response rates with neoadjuvant therapy for HER2-positive disease, but again, this is a chemo-free regimen so that is encouraging for that 38% of patients that really didn't need chemotherapy.   And then the second primary endpoint, and this was what we saw basically for the first time with the 2023 ASCO Meeting, was results for the 3-year invasive disease-free survival in Group B or this experimental de-escalation group. And ultimately it was shown that the three-year invasive disease-free survival and the intent to treat group B population was 95.4%, which met its statistical endpoint, or, basically the null hypothesis was rejected. They just needed some sort of outcome that was not worse in terms of the 3-year invasive disease-free survival of 89%.   And then looking actually at the patients that kind of did the best. So, the patients that were PET responders and achieved a complete response at the time of surgery and therefore really only ever received Herceptin-PERJETA, their three-year invasive disease-free survival was 98.8%. So, really very good. Additional endpoints they looked at in Group A and Group B were favorable in terms of three-year invasive disease-free survival in Group A, and then three-year distant disease-free survival and three-year overall survival in both groups, all approximately 98%. So, very favorable.   So, ultimately, these findings reflect a potential role for a chemotherapy-free treatment approach for some patients with early-stage HER2-positive breast cancer. And this particular study, they used PET/CT to influence chemotherapy decision-making, which potentially identified 1 in 3 patients who can omit chemotherapy. With that, 80% of patients receiving the response with a PET/CT, and then of that, 80%, again, 38% actually having that complete response. And ongoing work is also being done to look at other mechanisms to assess for an opportunity to de-escalate with MRI imaging or HER2DX testing to again try to identify patients who can potentially defer chemotherapy in this setting. I did not see from the results what proportion of patients were hormone receptor-positive, which I think is also interesting when thinking about chemotherapy de-escalation, can you lean a little bit more heavily on endocrine therapy? Perhaps we'll get that data in the future.   Dr. Allison Zibelli: That's a very important point.  I would like to thank you, Dr. Heeke, for coming on the podcast today and sharing your valuable insights with us. We really appreciate it.  Dr. Arielle Heeke: Absolutely. It was a great meeting to dive into. It's always exciting to see what comes out of ASCO in the breast space. We're usually well represented there, and I hope that these studies will lead to further exploration.   Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find links to all abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.  Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Follow today's speakers:   Dr. Allison Zibelli   Dr. Arielle Heeke  @HeekeMD     Follow ASCO on social media:    @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn      Disclosures:    Dr. Allison Zibelli:    None Disclosed   Dr. Arielle Heeke:   Honoraria: Merck  Consulting or Advisory Role: Jazz Pharmaceuticals, Caris Life Sciences, Amgen, Daiichi Sankyo/Astra Zeneca, Pfizer, AstraZeneca, Menarini, Genome Insight  Speakers' Bureau: Daiichi Sankyo/Astra Zeneca      

This week on Pharm5: Walmart, CVS Claim Pharmacist Shortage Changes to Paxlovid, Lagevrio, and COVID vaccines EzriCare eyedrops linked to bacterial outbreak New FDA approvals: Jayprica, Orserdu, Jesduvroq GoodRx sells health info to advertisers Connect with us! Listen to our podcast: Pharm5 Follow us on Twitter: @LizHearnPharmD References: Valinsky J. CVS and Walmart Cut Pharmacy Hours, close some locations earlier, citing staffing shortage | CNN business. CNN. http://bit.ly/3RpgS2F. Published January 27, 2023. Accessed February 2, 2023. Keagy J. American Pharmacists Association on move to cut pharmacy hours. American Pharmacists Association. http://bit.ly/3JB0v0Q. Published January 30, 2023. Accessed February 2, 2023. Paxlovid, Lagevrio prescriptions no longer need a positive COVID-19 test. Becker's Hospital Review. http://bit.ly/3DC3Jh3. Published February 1, 2023. Accessed February 2, 2023. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. New York, NY: Pfizer. https://bit.ly/3RvXNvO. Revised February 1, 2023. Accessed February 2, 2023. Fact sheet for healthcare providers: emergency use authorization for Lagevrio (molnupiravir) capsules). Rahway, NJ: Merck & Co. https://bit.ly/3HsLo72. Revised February 1, 2023. Accessed February 2, 2023. Bulloch M. FDA Advisory Committee vote to simplify covid-19 regimen. Pharmacy Times. http://bit.ly/3jweY3t. Published February 1, 2023. Accessed February 2, 2023. O'Mary L. Bacterial outbreak linked to EzriCare eyedrops: CDC. Medscape. http://bit.ly/3l3tOz9. Published February 1, 2023. Accessed February 2, 2023. Update: Multistate Cluster of VIM- and GES-producing Carbapenem resistant Pseudomonas aeruginosa associated with Artificial Tears. https://bit.ly/3DDHrey. Published January 20, 2023. Accessed February 2, 2023. Center for Drug Evaluation and Research. Novel drug approvals for 2023. U.S. Food and Drug Administration. http://bit.ly/3wO6ckC. Accessed February 2, 2023. Pagliarulo N. FDA approves cancer drugs from Lilly, Menarini. BioPharma Dive. http://bit.ly/3DEgnfc. Published January 30, 2023. Accessed February 2, 2023. FDA approves first oral treatment for anemia caused by chronic kidney disease for adults on dialysis. U.S. Food and Drug Administration. http://bit.ly/3RsL64E. Accessed February 2, 2023. FTC enforcement action to Bar Goodrx from sharing consumers' sensitive health info for advertising. Federal Trade Commission. http://bit.ly/3l50F6C. Published February 1, 2023. Accessed February 2, 2023.

"Abbiamo messo insieme persone che vivono ogni giorno situazioni di bambini che hanno subito violenze. Solamente dalla vita vera si possono ottenere risposte efficaci". Lo ha detto Lucia Aleotti, azionista e membro del Board di Menarini, a margine del primo incontro "Infanzia bruciata. Aiutiamoli a sorridere" organizzato dal Think Tank "On Radar".xl3/fsc

Osservare la società individuarne i problemi, mettere in campo idee, pensieri e soprattutto, attraverso il dialogo, cercare di migliorare il contesto in cui viviamo per mettere in moto cambiamento reali. È l'obiettivo del think tank On Radar, lanciato dalla Fondazione Internazionale Menarini, e coordinato da Massimo Scaccabarozzi, già presidente di Farmindustria.xb1/sat/gsl

Context Therapeutics CEO Martin Lehr joined Proactive's Stephen Gunnion with details of a clinical trial collaboration and supply agreement with The Menarini Group for Menarini's oral selective estrogen receptor degrader (SERD), elacestrant. Lehr explained that the collaboration with Menarini will explore the therapeutic potential of adding ONA-XR, Context's oral progesterone receptor antagonist, to elacestrant. "This is an agreement we've been working on for some time and we're very excited about it," Lehr said. "We think it will be an incredible positive for the company; an incredible positive for patients."

Lo scorso mercoledì 12 maggio, ai microfoni delle Donne al Volante,  con Liliana Russo e Katia De Rossi è tornato il direttore del mensile il Salvagente, Riccardo Quintili. In questo  incontro ci ha parlato di alcuni test effettuati sugli integratori anticolesterolo, svelando che uno su quattro non si scioglie nell'organismo. In merito alle sue ricerche, anche l'azienda farmaceutica Menarini ha ritirato il farmaco dal mercato ed è intervenuto anche il Ministero della Salute. Per saperne di più, riascolta l'intervista!

Nella giornata di giovedì 20 aprile, le nostre Donne al Volante, Lilly e Katia, hanno avuto ospite Riccardo Quintili, direttore del mensile Il Salvagente, pronto ad aiutare i consumatori. In questo appuntamento torna a parlarci di alcuni test fatti su integratori contro il colesterolo, perché molto spesso alcuni integratori non si disaggregano ovvero non si sciolgono come dovrebbero e non rilasciano il principio attivo che dovrebbe servire alle persone. In particolare è stato coinvolto il gruppo Menarini, dove tra i suoi prodotti sono stati trovati alcuni integratori che non funzionano come dovrebbero. Dopo accurati test fatti dall'azienda stessa, i prodotti sono stati ritirati dal commercio. Si tratta di un segnale molto importante e di un azienda intelligente che ha preso una sua posizione a riguardo.  

Marco Catenacci e Francesco Ruzzier presentano ABCinema con Blow Out.“Alla domanda "Che cos'è uno spettatore?" si potrebbe rispondere in tanti modi. Non solo perché ciascuno ha in mente una propria idea di spettatore, basata il più delle volte su di sé e sui propri comportamenti, ma anche perché nel corso del tempo guardare un film ha assunto significati culturali e sociali molto diversi tra loro.” Il libro "La grande illusione. Storie di uno spettatore" scritto da Roy Menarini ed edito da Mimesis, comincia così, con una domanda tanto aperta e complessa quanto cruciale. Scavando nei ricordi della sua vita da spettatore, l'autore ricostruisce infatti un'appassionante autobiografia della sua esperienza cinefila, architettando una narrazione episodica che prova a fondere lo sguardo sentimentale con quello accademico, la nostalgia con l'analisi dei media. Dalla meraviglia delle prime volte al cinema, coi genitori e in solitaria, all'intensificazione dell'esperienza vissuta nel contesto dei festival, dalle sale parrocchiali ai cineclub, dai multiplex al divano di casa propria, dagli occhialini per la visione in 3D alle mascherine per contenere il contagio : ad emergere non sono soltanto i film, ma soprattutto i contesti, i ricordi, le esperienze di visione; per l'appunto, le tante…storie di uno spettatore.Nella puntata di ABCinema con Blow Out che state per ascoltare saremo allora in compagnia di Roy Menarini, critico cinematografico e docente universitario, e affronteremo tanti dei temi indagati nel suo ultimo libro. Buio in sala, iniziamo.

In this episode, Ayesha discussed Gilead Science's lawsuit against a network of distributors selling counterfeits of the company's best-selling HIV drugs Biktarvy and Descovy. The drugs were being sold in pharmacies across several states. Gilead said it had been working with the US Marshals and local law enforcement to conduct seizures of over 85,000 bottles of the counterfeit drugs. Gilead says it's taking action to ensure the counterfeits are removed from circulation. The editorial team talked about the significant dangers of counterfeit drugs with respect to patient safety and that stricter regulations around tracking and audits at pharmacies should be implemented to prevent the distribution of counterfeit products.The editorial team also discussed Menarini Diagnostics' new PCR-based COVID-19 test that can detect all of the variants of SARS-CoV-2, including Omicron. Read the full articles here: Gilead Sues Distributors Selling Counterfeit HIV DrugsMenarini Diagnostics' New COVID-19 Test Detects Variants Including OmicronFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Ben trovati nel podcast della serie Tax Talks dello Studio Paolo Gaeta. Il tema di questa puntata è l'acquisto di immobili negli stati uniti d'america da parte di soggetti residenti in Italia. Ne parliamo con Elettra Menarini, nata a Bologna, prima avvocato in Italia e poi negli Usa, specializzatasi all'Università di San Diego e New York. Da alcuni anni svolge la sua attività legale a San Diego, California. Elettra assiste private client, famiglie multi-giurisdizionali e società in un'ampia gamma di questioni giuridiche statunitensi e internazionali. In particolare, Elettra è una esperta di fiscalità e pianificazione patrimoniale. Ascolta il PODCAST su altre Fonti Digitali✅ Studio Gaeta Podcast su Spotify✅ Studio Gaeta Podcast su iTunes ✅ Studio Gaeta Podcast su Google✅ Studio Gaeta Podcast su Amazon

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano Lagravinese.In questa puntata parliamo di:Menarini Terapie Geniche, Vaccinazione Covid, CNR, Vaccino Moderna, Intelligenza Artificiale.Aziende: Menarini, Vysioneer.Persone: Fabio Ciceri (Ospedale San Raffaele), Maria Chiara Carrozza (Cnr), Jen-Tang Lu (Vysioneer).Nuove terapie: Vaccino, VBrain.Patologie: COVID-19, tumori.Lavoro: Remote Site Monitor, Clinical Project Manager, Clinical Study Manager.Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su:www.telegram.me/pharmapillswww.facebook.com/pharmapills/

DREAM ON FLY

Ripartire dal benessere, riscoprire dove abitiamo e ritrovare interesse per le aree interne. Sono questi alcuni dei punti su cui lavora la Cabina di Regia “Benessere Italia” presieduta dalla Presidente Filomena Maggino. Quest'oggi, 26 Gennaio 2021, è un giorno storico per la Toscana perché in Palazzo Vecchio proprio la Professoressa Maggino e il Presidente della Società della Salute del Mugello Filippo Carlà Campa (Sindaco di Vicchio ndr) hanno firmato il primo accordo quadro nella nostra regione. Dopo Basilicata e Puglia, e con in ponte gli accordi in Irpinia e Liguria, la Cabina di Regia di Palazzo Chigi e la SDS del Mugello si sono impegnati, insieme, per dare del benessere ai cittadini del Mugello. Come? Affrontando temi come la questione energetica, quella digitale e tecnologica piuttosto che superare povertà e diseguaglianze e promuovere salute e benessere individuale e collettivo. Una collaborazione tra ricerca, imprese e pubblica amministrazione che riporti al centro i cittadini e le comunità anche grazie ad esperienze analoghe fatte in altri territori. A margine della firma la Professore Maggino, Presidente della Cabina di Regia ha detto: “E' importante perché la cabina di regia ha accolto molti stakeholder a Palazzo Chigi, ma con l'emergenza sanitaria abbiamo deciso di andare sul territorio”. Su questo accordo ha aggiunto: “Questo significa ripartire dalle aree interne, che forse non hanno sofferto troppo l'epidemia ma che stavano soffrendo da decenni. Il primo segnale è quello di creare una serie di accordi quadro con reti di comuni e con aree interne, anche per consentire una ripartenza su temi specifici orientati alla promozione del benessere. Abbiamo già firmato questi accordi in Puglia e Basilicata, poi ci saranno in Irpinia e Liguria, siamo felici che in Toscana sia la SdS del Mugello la prima a firmare un accordo con noi” “La Cabina di Regia – ha aggiunto la Professoressa Maggino - è formata dai rappresentanti fiduciari dei Ministri. Quando verifichiamo la possibilità di presentare un progetto, lo presentiamo ai rappresentanti dei ministri. In quel contesto possiamo valutare in quale direzione poter attingere dai territori. Nel lockdown è stato emozionante sentir dire di “dover ripartire” dal concepire il dove abitiamo: ecco perché questo interesse per le aree interne. Là si può trovare una qualità della vita migliore, per i tanti motivi che sappiamo, ma per consentire questo dobbiamo sostenere la rimodellazione dei servizi territoriali alla persona e una mobilità con spostamenti più agevoli” L'accordo è arrivato al termine di una lunga due giorni di incontri. Dalla Knorr-Bremse passando per la Menarini piuttosto che gli incontri politici con Eugenio Giani, Camilla Sanquerin, Simone Bezzini. Ma che cosa ha visto la Presidente della Cabina di Regia: “L'area fiorentina rappresenta delle eccellenze produttive che vanno incoraggiate, sostenute e valorizzate per far si che questo territorio, storicamente ricco di iniziativa e attività, non veda questa ricchezza andare persa. Per fare ciò non vanno attivati solo i sistemi finanziari, le aziende chiedono di lavorare nel proprio paese, nel proprio territorio: portano un bene cittadini, ovvero il lavoro”. E ha concluso: “Ho trovato un territorio che deve riflettere su una cosa. Aver investito solo nell'attività turistica ha portato fragilità. Il turismo si attiva e si attrae se sul territorio c'è una attività propria che è espressione di quel territorio e non solo accoglienza”.

La ricetta italiana per il Recovery Fund e il discorso sullo stato dell’Unione di Ursula Von der Leyen. Ne parliamo con Alberto Orioli, vicedirettore del Sole 24 Ore, e con Barbara Fiammeri, commentatrice politica del Sole 24 Ore, con la quale facciamo anche un punto sulla giornata politica. Da Menarini un test Covid che dà risultati in 12 secondi. Con noi Sandra Zampa, Sottosegretaria alla Salute, che commenta anche la proposta dell'Assessore agli Affari Legali della Regione Piemonte Maurizio Marrone (anche lui nostro ospite) per lo stop all'aborto farmacologico in Day Hospital. Scuola: i sindacati confermano manifestazione in piazza del 26 settembre. Sentiamo Maddalena Gissi, Segretaria Generale Cisl Scuola.

La ricetta italiana per il Recovery Fund e il discorso sullo stato dell’Unione di Ursula Von der Leyen. Ne parliamo con Alberto Orioli, vicedirettore del Sole 24 Ore, e con Barbara Fiammeri, commentatrice politica del Sole 24 Ore, con la quale facciamo anche un punto sulla giornata politica. Da Menarini un test Covid che dà risultati in 12 secondi. Con noi Sandra Zampa, Sottosegretaria alla Salute, che commenta anche la proposta dell'Assessore agli Affari Legali della Regione Piemonte Maurizio Marrone (anche lui nostro ospite) per lo stop all'aborto farmacologico in Day Hospital. Scuola: i sindacati confermano manifestazione in piazza del 26 settembre. Sentiamo Maddalena Gissi, Segretaria Generale Cisl Scuola.

Menarini Asia Pacific has launched a weekly radio broadcast for employees across APAC amidst Covid-19. Christopher Tay, Group Chief Admin Officer & Member Board Of Directors, Menarini Asia Pacific Holdings shares the importance of engaging with their employees during this Covid-19 period and the company’s perspective on managing the Menarini in this current environment.

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano Lagravinese.In questa puntata parliamo di:AbbVie, Menarini, Intelligenza Artificiale, Antibiotico-resistenza, Car-T, Trapianto microbiota fecale.Aziende: AbbVie, Menarini, Johnson & Johnson.Persone: Daniele Toia (AbbVie), Elcin Barker Ergun (Menarini).Nuove terapie: Car-T, FMT (trapianto di microbiota fecale).Patologie: Fibrosi cardiaca, Infezioni da Clostridioes difficile.Lavoro: Medical Science Liaison (Triveneto), Site Manager/CRA (Cologno Monzese), CRA I-II home based (Milano).Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su:www.telegram.me/pharmapillswww.facebook.com/pharmapills/

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano Lagravinese.In questa puntata parliamo di:AbbVie, Menarini, Intelligenza Artificiale, Antibiotico-resistenza, Car-T, Trapianto microbiota fecale.Aziende: AbbVie, Menarini, Johnson & Johnson.Persone: Daniele Toia (AbbVie), Elcin Barker Ergun (Menarini).Nuove terapie: Car-T, FMT (trapianto di microbiota fecale).Patologie: Fibrosi cardiaca, Infezioni da Clostridioes difficile.Lavoro: Medical Science Liaison (Triveneto), Site Manager/CRA (Cologno Monzese), CRA I-II home based (Milano).Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su:www.telegram.me/pharmapillswww.facebook.com/pharmapills/

If anyone on planet Earth would know about GM's diesel program - it's Nicola Menarini. He's GM's Chief Engineer and Program Manager of Duramax. Back in February 2017, he talked to the Diesel Performance Podcast about everything related to the new generation Duramax - how it performs and other engineering considerations. Special Thanks to Our Sponsors: Wehrli Custom Fabrication WCFab.com Exergy Performance exergyperformance.com Calibrated Power Solutions calibratedpower.com    

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: LabCorp, IQVIA, Syneos Health, PAREXEL, PRA Health Sciences, PPD, Charles River Laboratories International, ICON, Wuxi Apptec, Medpace, Menarini, Bayer, Monsanto, Enthera, Trianni, Celgene, Prothena, AIFA, FADOI, Novo Nordisk, Icon, Synteract.Persone: Eric Cornut (Menarini), Lucia Aleotti (Menarini), Paolo Fiorina (Enthera), Andrea Fontanella (FADOI), Lisa Maier (European Molecular Biology Laboratory).Nuove terapie: semaglutide. Patologie: Alzheimer, obesità.Lavoro: Clinical Trial Educator, CRA.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: LabCorp, IQVIA, Syneos Health, PAREXEL, PRA Health Sciences, PPD, Charles River Laboratories International, ICON, Wuxi Apptec, Medpace, Menarini, Bayer, Monsanto, Enthera, Trianni, Celgene, Prothena, AIFA, FADOI, Novo Nordisk, Icon, Synteract.Persone: Eric Cornut (Menarini), Lucia Aleotti (Menarini), Paolo Fiorina (Enthera), Andrea Fontanella (FADOI), Lisa Maier (European Molecular Biology Laboratory).Nuove terapie: semaglutide. Patologie: Alzheimer, obesità.Lavoro: Clinical Trial Educator, CRA.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: EMA, Kite Pharma, Gilead, Sangamo Therapeutics, Assogenerici, Amazon, Perrigo, Novartis, Roche, Flatiron Health, FDA, Astrazeneca, Bausch and Lomb, PRA Health Sciences, Menarini. Persone: Enrique Häusermann (Assogenerici), Susanne Schaffert (Novartis), Vincenzo Palermo (Astrazeneca), Antonio Iavarone (Besta), Anna Lasorella (Besta).Nuove terapie: durvalumab.Patologie: tumore al polmone, glioblastoma. Lavoro: Pharmacovigilance Specialist, CRA, Regulatory Affairs Officer.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: EMA, Kite Pharma, Gilead, Sangamo Therapeutics, Assogenerici, Amazon, Perrigo, Novartis, Roche, Flatiron Health, FDA, Astrazeneca, Bausch and Lomb, PRA Health Sciences, Menarini. Persone: Enrique Häusermann (Assogenerici), Susanne Schaffert (Novartis), Vincenzo Palermo (Astrazeneca), Antonio Iavarone (Besta), Anna Lasorella (Besta).Nuove terapie: durvalumab.Patologie: tumore al polmone, glioblastoma. Lavoro: Pharmacovigilance Specialist, CRA, Regulatory Affairs Officer.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: EMA, Teva, Bayer, Menarini, Allergan, Repros Therapeutics, Novartis, FDA, Sanofi, Eli Lilly, Gilead, Kite Pharma, Ionis Pharmaceuticals, Roche.Persone: Jörg Reinhardt (Novartis), Franco Cavalli (Istituto Oncologico della Svizzera Italiana), Alberto Albanese (Humanitas).Nuove terapie: Kymriah, Admelog, Humalog, emicizumab, Yescarta.Patologie: infertilità, leucemia, diabete, emofilia A, linfoma non-Hodgkin, sclerosi laterale amiotrofica, tubercolosi, Còrea di Huntington.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: EMA, Teva, Bayer, Menarini, Allergan, Repros Therapeutics, Novartis, FDA, Sanofi, Eli Lilly, Gilead, Kite Pharma, Ionis Pharmaceuticals, Roche.Persone: Jörg Reinhardt (Novartis), Franco Cavalli (Istituto Oncologico della Svizzera Italiana), Alberto Albanese (Humanitas).Nuove terapie: Kymriah, Admelog, Humalog, emicizumab, Yescarta.Patologie: infertilità, leucemia, diabete, emofilia A, linfoma non-Hodgkin, sclerosi laterale amiotrofica, tubercolosi, Còrea di Huntington.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Sanofi, Zentiva, Abbvie, Alector, Chiesi Farmaceutici, Protalix BioTherapeutics, Eli Lilly, Menarini, Molteni, Kedrion, High Research, FDA, AIFA, Amgen.Persone: Hubert de Ruty (Sanofi), Marco Grespigna (Zentiva), Lorenzo Cottini (High Research), Mario Melazzini (AIFA), Shalini Shah (UC Irvine), Alberto Mantovani (Humanitas Ospedale Milano), Cecilia Garlanda (Humanitas Ospedale Milano).Nuove terapie: etelcalcetide.Patologie: Alzheimer, malattia di Fabry, emicrania, cancro, AIDS, iperparatiroidismo.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Sanofi, Zentiva, Abbvie, Alector, Chiesi Farmaceutici, Protalix BioTherapeutics, Eli Lilly, Menarini, Molteni, Kedrion, High Research, FDA, AIFA, Amgen.Persone: Hubert de Ruty (Sanofi), Marco Grespigna (Zentiva), Lorenzo Cottini (High Research), Mario Melazzini (AIFA), Shalini Shah (UC Irvine), Alberto Mantovani (Humanitas Ospedale Milano), Cecilia Garlanda (Humanitas Ospedale Milano).Nuove terapie: etelcalcetide.Patologie: Alzheimer, malattia di Fabry, emicrania, cancro, AIDS, iperparatiroidismo.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Biogenera, Abbvie, Menarini, Janssen, Roche, Sanofi, Boehringer Ingelheim, Celgene, Novartis.Persone: Fabrizio Greco (Abbvie), Lucia e Alberto Giovanni Aleotti (Menarini), Eric Cornut (Menarini), Patrizia Menassero (Partito Democratico), Emilia Grazia De Biasi (Commissione Sanità del Senato), Loredana Bergamini (Janssen), Annarita Gabriele (Roche), Brigitte Pouletty-Lefebvre (Sanofi), Sabine Greulich (Boehringer Ingelheim), Bruno Strigini (Novartis).Nuove terapie: BGA002, ridociclib.Patologie: neuroblastoma, malattie cardiovascolari, artrite psoriasica, psoriasi, mieloma multiplo, carcinoma del pancreas, carcinoma mammario, nistagmo.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Biogenera, Abbvie, Menarini, Janssen, Roche, Sanofi, Boehringer Ingelheim, Celgene, Novartis.Persone: Fabrizio Greco (Abbvie), Lucia e Alberto Giovanni Aleotti (Menarini), Eric Cornut (Menarini), Patrizia Menassero (Partito Democratico), Emilia Grazia De Biasi (Commissione Sanità del Senato), Loredana Bergamini (Janssen), Annarita Gabriele (Roche), Brigitte Pouletty-Lefebvre (Sanofi), Sabine Greulich (Boehringer Ingelheim), Bruno Strigini (Novartis).Nuove terapie: BGA002, ridociclib.Patologie: neuroblastoma, malattie cardiovascolari, artrite psoriasica, psoriasi, mieloma multiplo, carcinoma del pancreas, carcinoma mammario, nistagmo.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Pfizer, Novartis, Roche, Sanofi, Uk Biobank, GSK, Regeneron Genetics, AriSla, Nerviano Medical Sciences, Trovagene, Menarini, Eli Lilly, AIFA, Merk, Aiom, Newron e Zambon.Persone: Amy Brown (EP Vantage), Maurizio de Cicco (Roche), Andrea Agazzi (NMS Group), Romano Marabelli (Ministero della Salute), Dan L. Longo (Università di Harvard), Carmine Pinto (Aiom), Federica Meloni (Università di Pavia).Nuove terapie: Humira, Revlimid, Ocrevus, Dupilumab, PCM-075, imatinib, avelumab, deflazacort, safinamide, evolocumab.Patologie: sclerosi multipla, dermatite atopica, sclerosi laterale amiotrofica, leucemia mieloide cronica, carcinoma a cellule di Merkel, mesotelioma pleurico maligno, distrofia muscolare di Duchenne, malattie cardiovascolari. Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Per approfondire gli argomenti visita il sito web www.PharmaPills.it e clicca mi piace sulla pagina facebook “PharmaPills”.Per segnalazioni sugli argomenti da trattare in questo podcast puoi scriverci su pharmapills [at] carrieranelfarmaceutico.com mentre per ulteriori informazioni e nuovi contenuti in tempo reale ti invitiamo invece a unirti al canale telegram telegram.me/pharmapills. Aiutaci a crescere con una recensione a 5 stelle su iTunes!Gli autori di PharmaPills sono:– Linda Scannavini (voce e regia)– Giorgia Latteri (montaggio e regia)– Stefano Lagravinese (coordinamento e regia)

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Pfizer, Novartis, Roche, Sanofi, Uk Biobank, GSK, Regeneron Genetics, AriSla, Nerviano Medical Sciences, Trovagene, Menarini, Eli Lilly, AIFA, Merk, Aiom, Newron e Zambon.Persone: Amy Brown (EP Vantage), Maurizio de Cicco (Roche), Andrea Agazzi (NMS Group), Romano Marabelli (Ministero della Salute), Dan L. Longo (Università di Harvard), Carmine Pinto (Aiom), Federica Meloni (Università di Pavia).Nuove terapie: Humira, Revlimid, Ocrevus, Dupilumab, PCM-075, imatinib, avelumab, deflazacort, safinamide, evolocumab.Patologie: sclerosi multipla, dermatite atopica, sclerosi laterale amiotrofica, leucemia mieloide cronica, carcinoma a cellule di Merkel, mesotelioma pleurico maligno, distrofia muscolare di Duchenne, malattie cardiovascolari. Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Per approfondire gli argomenti visita il sito web www.PharmaPills.it e clicca mi piace sulla pagina facebook “PharmaPills”.Per segnalazioni sugli argomenti da trattare in questo podcast puoi scriverci su pharmapills [at] carrieranelfarmaceutico.com mentre per ulteriori informazioni e nuovi contenuti in tempo reale ti invitiamo invece a unirti al canale telegram telegram.me/pharmapills. Aiutaci a crescere con una recensione a 5 stelle su iTunes!Gli autori di PharmaPills sono:– Linda Scannavini (voce e regia)– Giorgia Latteri (montaggio e regia)– Stefano Lagravinese (coordinamento e regia)

Now is a good time to work in the diesel industry, according to Nicola Menarini. He should know, he's been involved in diesel engineering for nearly 30 years working for multiple manufacturers worldwide. Today Nicola is GM's Chief Engineer & Program Manager for Duramax where he's overseeing the rollout the next Generation Duramax - the 6.6L L5P, 2.8L Duramax and the 1.6L diesel power the new Chevy Cruze. Nicola explains to Diesel Performance Podcast's Nick Priegnitz, Danny Voss, and Paul Wilson some of the forthcoming changes to the GM diesel line-up. The new Chevy Cruze will feature a manual transmission because that's what customers said they wanted. The future will also include diesel configurations of a medium size SUV and Van. The conversation also covers exhaust gas temperatures, regen, transient response, and the removal of soot and NOx emissions from diesel exhaust.   

il caso Sofosbuvir; il processo Menarini; il difficile trasporto per gli studenti disabili

il caso Sofosbuvir; il processo Menarini; il difficile trasporto per gli studenti disabili

il caso Sofosbuvir; il processo Menarini; il difficile trasporto per gli studenti disabili

David Saiz nos cuenta su experiencia dentro del departamento de Customer Service de Menarini España como Trade and Customer Service Manager, en el trabajó durante dos décadas. Nos explica el valor estratégico de la función de Customer Service, catalizador del cambio organizativo en Menarini y basado en una elección de herramientas tecnológicas que le han permitido llevar a cabo este cambio. La alineación de departamentos, la elección y el seguimiento de KPIs y el liderar el cambio con procedimientos claves y perfiles adecuados, son unos de los elementos clave de éxito para la eficiencia del Customer Service según David, que por supuesto cuenta con el apoyo de la dirección general.

En el momento de la grabación de este audio, David Saiz era Trade and Customer Service Manager de Grupo Menarini España, actualmente trabaja para el grupo Kern Pharma, también cliente de Esker. David comparte con nosotros su experiencia con la solución de automatización de Esker en la gestión de sus pedidos de clientes. Nos habla de la alineación de estrategia, trazabilidad, KPIs, ahorros de 10.000 euros por eliminación de errores manuales, y otras aportaciones de Esker, tanto desde un punto de vista cualitativo (mejora de procesos, dedicación de los agentes a la gestión de la demanda de los clientes antes saturados con tareas sin valor añadido), como cuantitativo (reducción de un 75% del tiempo de gestión de pedidos) y también medioambientales (reducción de papel, máquinas y consumibles). En palabras de David, “recomendaría a Esker por su potente herramienta que ayuda a la transformación digital, y por su dedicación al cliente”

¿Tiene el Customer Service el lugar que realmente se merece dentro de las organizaciones? ¿De quién debería depender este departamento? ¿Cómo de estratégica es la labor que se realiza? Reyes Eguilior de Alpargatas Europa, Ramón Bonet de Sanofi España o David Saiz ex trabajador de Menarini, actual Kern Pharma, responden a estas preguntas.

-Leucemia, Studio Florence: Febuxostat, “farmaco-spazzino” riduce i danni da chemioterapia Ogni anno sono oltre 25.000 gli italiani che devono fare i conti con tumori ematologici come leucemie e linfomi, guaribili oggi nel 70 % dei casi, ma che espongono al rischio di uno degli effetti collaterali più temibili della chemioterapia, la cosiddetta sindrome da lisi tumorale che si verifica quando tante cellule neoplastiche, distrutte dai farmaci, liberano nell'organismo sostanze tossiche per i reni, in particolare acido urico. Questo problema riguarda circa il 3-20% dei malati con tumori ematologici, ma l'incidenza sale fino al 30% negli under 18. Prevenire la lisi, che può provocare insufficienza renale in circa il 30% dei casi e nel 5% dei pazienti essere addirittura mortale, potrebbe presto diventare più semplice con febuxostat, un farmaco già ampiamente usato per ridurre l’acido urico nei malati di gotta: febuxostat, sicuro e ben tollerato, fin dal primo giorno di trattamento si comporta come uno “spazzino” diminuendo di circa il 30% i livelli di acido urico nel sangue rispetto all'allopurinolo, il farmaco impiegato ormai da trent'anni. Lo dimostrano i dati preliminari dello studio FLORENCE (Febuxostat for tumor Lysis syndrOme pREvention iN hematologiC malignanciEs), la più ampia sperimentazione clinica internazionale mai condotta in questo ambito, presentati oggi in anteprima a Firenze, la città dove lo studio è stato disegnato, con un investimento di circa 50 milioni di euro per l’intero programma di sviluppo di Febuxostat nella sindrome da lisi tumorale. -Negli ultimi 4 anni persi 1700 posti di specializzazione “In Italia negli ultimi 4 anni abbiamo perso 1.700 posti destinati alle scuole di specializzazione. I posti sono circa la metà di quelli necessari. Siamo in controtendenza rispetto al resto dell'Europa e del mondo che richiede specializzazione e cultura per la scienza. Rischiamo di laureare ottimi professionisti ma perdere tutti i potenziali scienziati e innovatori”. Lo ha dichiarato Andrea Lenzi, Presidente del Consiglio universitario nazionale, Cun, Ordinario di endocrinologia alla Sapienza Università di Roma in occasione dell’appuntamento annuale che ha avuto luogo oggi in Senato, promosso dalla Fondazione Lilly nell’ambito del progetto “La Ricerca in Italia: un’Idea per il Futuro”. L’iniziativa, arrivata ormai alla sua sesta edizione, è tesa a favorire la cultura della ricerca in Italia proponendo un nuovo modello basato su meritocrazia, trasparenza e valorizzazione economica. Anche quest’anno la Fondazione Lilly ha confermato il suo impegno assegnando una borsa di studio a un giovane ricercatore e aprendo il nuovo bando di ricerca. -Diabete: Ridurre il rischio di ipoglicemia Campagna MSD “L’educazione innanzitutto” Per le persone con diabete, la gestione delle crisi ipoglicemiche è un obiettivo imprescindibile, di cui spesso il paziente è poco a conoscenza e per il quale è necessaria una consapevolezza più diffusa.A 7 anni dal lancio di sitagliptin, MSD Primary Care Diabete presenta “L’educazione innanzitutto”, un nuovo progetto educazionale che ha come obiettivo quello di informare sulla consapevolezza del problema ipoglicemia, sulle complicanze ad essa associate e sul ruolo della sua corretta gestione. La campagna prende avvio con il lancio di un cortometraggio, interpretato dagli attori Enzo Decaro e Marta Zoffoli, che pone l’accento sui rischi che derivano dal sottovalutare l'ipoglicemia. Il cortometraggio si rivolge alle persone con diabete con la finalità educazionale di far comprendere cosa sia l'ipoglicemia e quali siano le complicanze ad essa associate. Il corto vuole inoltre essere uno spunto di riflessione per i medici e gli esperti di diabetologia circa l'importanza della consapevolezza da parte dei pazienti del problema ipoglicemia e la necessità di una sua corretta gestione. -Un palloncino per ridurre la fame In Italia il 25% dei bambini è in sovrappeso, mentre il 13% è addirittura obeso. Non sempre, purtroppo, le strategie dietetiche-comportamentali riescono a mettere sotto controllo il problema per cui si rendono necessari trattamenti non convenzionali. Tra questi il metodo meno invasivo prevede l’inserimento di un palloncino che viene gonfiato all’interno dello stomaco per indurre il senso di sazietà e aiutare così il paziente a seguire una dieta più corretta e dimagrire in maniera significativa. Al Bambino Gesù di Palidoro è stata utilizzata per la prima volta in campo pediatrico una metodica che permette di posizionare i palloncini semplicemente ingoiando una pillola. Fino a poco tempo fa, infatti, questi palloncini venivano inseriti per via endoscopica, ma oggi è disponibile una procedura alternativa che permette al paziente di inghiottire semplicemente una “pillola”, del peso di appena 6 grammi, che verrà poi gonfiata all’interno dello stomaco attraverso un sottile tubicino (dal diametro inferiore al millimetro). Costituito da una membrana sottilissima, il palloncino è studiato per resistere agli acidi dello stomaco ed è praticamente indistruttibile. Gonfiandolo con un gas più leggero dell’aria - l’azoto - facciamo sì che vada a posizionarsi nella parte alta dello stomaco, nel fondo gastrico, interagendo con i recettori dell’appetito ed inducendo un senso di sazietà precoce.